Orphan designation: asedebart Treatment of Cushing's syndrome of endogenous origin, 20/08/2026 Positive
Orphan designation: asedebart Treatment of Cushing's syndrome of endogenous origin, 20/08/2026 Positive
Orphan designation: asedebart Treatment of Cushing's syndrome of endogenous origin, 20/08/2026 Positive
Orphan designation: zolacabtagene autoleucel Treatment of systemic sclerosis, 20/08/2026 Positive
Orphan designation: zolacabtagene autoleucel Treatment of PLN R14del cardiomyopathy, 20/08/2026 Positive
Orphan designation: 4-(4-Bromo-2-oxo-3H-benzimidazol-1-yl)-N-(4-iodophenyl)piperidine-1-carboxamide Treatment of idiopathic pulmonary fibrosis, 20/08/2026 Positive
Orphan designation: adeno-associated viral vector serotype 6 containing the truncated human HCN4 gene treatment of congenital complete heart block, 20/08/2026 Positive
Orphan designation: paltusotine Treatment of carcinoid syndrome, 20/08/2026 Positive
Orphan designation: imsidolimab Treatment of generalised pustular psoriasis, 20/08/2026 Positive
Orphan designation: efgartigimod alfa Treatment of idiopathic inflammatory myopathy, 19/10/2026 Positive
Orphan designation: niraparib tosilate monohydrate Treatment of glioma, 19/10/2026 Positive
Orphan designation: 6-(6-(((1R,2R,3S,5S)-2-Fluoro-9-azabicyclo[3.3.1]nonan-3-yl)(methyl)amino)pyridazine-3-yl)-2-methylbenzo[d]oxazol-5-ol Treatment of Huntington’s disease, 19/10/2026 Positive